drugset / Trial / NCT03760523
Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Terminated
27 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Minneamrita Therapeutics LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is to determine the safety and recommended dosing of Minnelide in Acute Myeloid Leukemia (AML)
Timeline
- Start
- 2019-04-18
- Primary completion
- 2023-10-09
- Completion
- 2023-10-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Minnelide | Small molecule | 0.5 mg | Oral |
| Subject | Minnelide | Small molecule | 0.75 mg | Oral |
| Subject | Minnelide | Small molecule | 1 mg | Oral |
| Subject | Minnelide | Small molecule | 1.25 mg | Oral |